Ketamine clinical trials at UCLA
1 in progress, 0 open to eligible people
Sorry, not yet accepting patients
This multicenter, triple-blind, phase 2, randomized controlled trial will evaluate the efficacy and safety of psilocybin therapy compared to an active control in treating demoralization in adults near the end of life (≤2 years life expectancy).
Our lead scientists for Ketamine research studies include Charles S. Grob, M.D..